BETA · In development—Rankings and features improve every week.Spotted an error?Tell us →
Sign in / Register

+ND Capital

Portfolio in Switzerland · United States: 2 funded startups tracked by Uback, 2 of them in a ranking.

Portfolio on Uback2startups, 2 countries
In a ranking2ranked by AI-estimated valuation
On the Radar0eligible, not ranked
Latest deal trackedJun 2025Visby Medical

Portfolio on Uback

Sorted by Uback rank, then Radar by last round
CompanyUbackSectorRound backedValuation (AI)
HAYA Therapeutics#32 SwitzerlandBiotech › RNA medicinesSeries A · USD 65M · May 2025Hundreds of M$
Visby Medical#11 In-vitro diagnosticsHealthtech › Medtech › In-vitro diagnosticsFinancing round (series not stated) · USD 55M · Jun 2025Hundreds of M$

Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.

By sector

Biotech1
Healthtech1

Deals tracked per year

22025

Co-investors

Sofinnova Partners · Earlybird · Eli Lilly · ATHOS · Alexandria · Catalio Capital Management · Cedars-Sinai · Blue Water Life Science Advisors · Pitango Ventures

Investors that joined the same rounds, as reported by public sources.

Last updated: Oct 2026Report a missing dealReport an error

Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.